Antibiotic resistance can develop to new antibiotics even before they reach the market, undermining their future ...
Tygacil (tigecycline)is a new, expanded broad-spectrum IV antibiotic that can be used for the treatment of a wide range of infections. Tygacil (tigecycline)is a new, expanded broad-spectrum IV ...
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
There appears to be a growing awareness among physicians and the intelligent lay public of some of the problems resulting from the widespread and indiscriminate use of antibiotics. This applies ...
“The key message is that some antibiotics that we routinely use for transplant patients . . . can really amplify the principal nemesis, which is graft-versus-host disease,” said James Ferrara of Mount ...
The study, "The Triple Combination of Meropenem, Avibactam, and a Metallo-β-Lactamase Inhibitor Optimizes Antibacterial Coverage Against ... work to develop broad spectrum metallo β-lactamase ...
With further research, doctors may be able to target specific types of bacteria in specific areas, reducing the need for broad-spectrum antibiotics. Putting their computer-modeling approach to the ...
aureus. Historically, antibiotics have been designed to kill off many different species of bacteria, giving clinicians an efficient and inexpensive way to treat a range of infections. But these ...
Recce’s new compound is a broad-spectrum antibiotic initially to be used intravenously against Escherichia coli and Staphylococcus aureus bacteria in the blood, including superbug forms.
Lab culture can take up to three days, and in the meantime patients with UTI symptoms are often prescribed broad-spectrum antibiotics that may be unnecessary, less effective, and encourage AMR.
In adults, recent studies suggest substantial opportunity to reduce broad-spectrum antibiotic use and shorten therapy. We sought to determine whether similar opportunity exists in children.